Results 131 to 140 of about 10,751 (182)

Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26. [PDF]

Appl Health Econ Health Policy
Forsyth JE, Achra M, Espinar JB, Hochmair M, Liepa AM, Lenox-Smith A, Puri T, Rajesh R, Sonksen MD, Summers Y, van der Wekken AJ, Jen MH, Ren S.   +12 more
europepmc   +1 more source

Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer. [PDF]

Front Oncol
Li D, Zhao X, Jia H, Cui R, Cao A, Huo L.   +5 more
europepmc   +1 more source

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma. [PDF]

Curr Oncol Rep
Wysocki PT, Chmiel P, Jassem J, Kraj L.
europepmc   +1 more source

Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel^®) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer. [PDF]

J Gastric Cancer
Kim HD, Kim S, Shin EJ, Lee J, Lee J, Lee M, Shin J, Ryu MH.   +7 more
europepmc   +1 more source

Capillary Hemangioma of the Breast Parenchyma Mimicking New Primary Cancer or Metastasis During Ramucirumab Therapy for Advanced Gastric Cancer. [PDF]

In Vivo
Kim HB, Lee YA, Kim SH, Park SG.
europepmc   +1 more source

Complete Response in Metastatic Rectal Cancer with Hepatic and Pulmonary Metastases Treated with Second-Line FOLFIRI plus Ramucirumab: A Case Report. [PDF]

Case Rep Oncol
Hasegawa M, Okayama H, Kitabori Y, Yamauchi N, Nakajima T, Matsumoto S, Sato N, Saito M, Kono K.   +8 more
europepmc   +1 more source

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer. [PDF]

ESMO Gastrointest Oncol
Wakatsuki T, Mashima T, Miyazaki N, Osumi H, Fukuoka S, Ooki A, Shimozaki K, Ogura M, Yoshino K, Udagawa S, Shinozaki E, Chin K, Ishida N, Seimiya H, Yamaguchi K.   +14 more
europepmc   +1 more source

Targetable genes associated with hematogenous metastasis in gastric cancer using the TCGA database. [PDF]

Korean J Clin Oncol
Yoo J, Kim HM, Jeong K, Yoo YR, Shin JY, Lee S, Lee S, Lee HS, Park KU, Kong SH, Park DJ, Lee HJ, Yang HK.   +12 more
europepmc   +1 more source

Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer. [PDF]

Cancer Immunol Res
Lim SH, An M, Heo YJ, Lee H, Min BH, Mehta A, Ahn S, Kim KM, Kim ST, Klempner SJ, Lee J.   +10 more
europepmc   +1 more source

A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas. [PDF]

Oncologist
Kim DW, Kim RD, Jimenez MM, Kim Y, Mehta R.   +4 more
europepmc   +1 more source